Newsroom

AI4CC qu'est-ce que c'est
Vidéos
AI4CC

AI4CC (Artificial intelligence for cervical cancer), what is it?

UneAi4CC_video
Vidéos
AI4CC

Cervical cancer: detect better, detect earlier with the help of AI, report in Malawi

Articles
AI4CC

Cervical cancer : when AI helps improve diagnosis

Cervical cancer is the second deadliest cancer in low- and middle-income countries (1). In Malawi in East Africa, where MSF operates, over 4,000 Malawian women fall sick with cervical cancer every year. With 2,905 deaths due to cervical cancer in 2020, the country also had the second highest rate of mortality (2). How can we explain such a high mortality rate from this disease which, in high-income countries, is easily preventable and generally less deadly?  The reasons include limited access to prevention and screening, and diagnoses that are not always reliable.

 

Clara Nordon, Director of the MSF Foundation, has just got back from a visit to Malawi with the MSF teams and tells us about the project led by the Foundation. Code name: AI4CC

Read more

Headline

Antibiogo 3
Articles
Antibiogo

Antibiogo ISO 13485 Certified, a First for a Humanitarian Project

In 2025, the Antibiogo application is seeing wide deployment, extending beyond MSF field operations. After being adopted by all MSF laboratories in 2024, the tool has also been integrated by local health authorities in several countries: Burkina Faso, Comoros, Guinea, Liberia, Mali, Central African Republic, Democratic Republic of the Congo, and Benin. This expansion marks a new era for Antibiogo: scaling up.

At the same time, the project team continued efforts to reach the highest level of quality standards, culminating in obtaining ISO 13485 certification. This unprecedented level of requirement for an NGO project reflects the excellence of the management practices implemented for this medical device project, for which MSF Foundation is the legal manufacturer.

Read more

MSF Foundation in Video

More articles

News

More articles

Publications

  • Publications
    Étude Fièvre Jaune

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
  • Publications
    Étude Fièvre Jaune

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
More articles

Press Review

More articles
No news for now.